China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the successful enrollment of the first batch of subjects in a Phase I clinical study in Australia for its pipeline candidate, SCB-1019, a respiratory syncytial virus (RSV) PreF trimeric subunit candidate vaccine.
The randomized, placebo-controlled Phase I study aims to assess the safety, reactivity, and immunogenicity of SCB-1019 across different dosages and in both young adult and elderly populations. Anticipated safety and immunogenicity results are expected in the second half of 2024.
SCB-1019 is a bivalent recombinant protein RSV candidate vaccine developed using Clover Bio’s unique innovative protein trimer Tag vaccine technology platform. The vaccine contains two stable fused pre conformational F antigens (A and B subtype RSVF proteins), offering a potential bivalent protection against RSV.- Flcube.com
